Esperion Therapeutics (NASDAQ:ESPR) was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued to investors on Thursday.

A number of other equities analysts have also weighed in on ESPR. Zacks Investment Research upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating and set a $51.00 target price for the company in a research report on Wednesday, October 3rd. BTIG Research initiated coverage on shares of Esperion Therapeutics in a research note on Tuesday, October 16th. They set a “buy” rating and a $82.00 price target on the stock. Cowen set a $82.00 price target on shares of Esperion Therapeutics and gave the company a “buy” rating in a research note on Friday, October 26th. Northland Securities raised shares of Esperion Therapeutics from a “market perform” rating to an “outperform” rating and set a $65.00 price target on the stock in a research note on Monday, October 29th. Finally, ValuEngine raised shares of Esperion Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, November 1st. Three research analysts have rated the stock with a sell rating, three have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. Esperion Therapeutics has a consensus rating of “Buy” and a consensus price target of $77.11.

Shares of NASDAQ:ESPR opened at $46.34 on Thursday. Esperion Therapeutics has a fifty-two week low of $33.06 and a fifty-two week high of $82.68. The firm has a market cap of $1.25 billion, a P/E ratio of -6.64 and a beta of 2.27.

Esperion Therapeutics (NASDAQ:ESPR) last issued its earnings results on Thursday, November 1st. The biopharmaceutical company reported ($1.86) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.58) by ($0.28). During the same period in the previous year, the company posted ($1.86) EPS. On average, analysts expect that Esperion Therapeutics will post -6.58 EPS for the current year.

In other news, major shareholder Target N. V. Biotech bought 80,000 shares of Esperion Therapeutics stock in a transaction dated Friday, January 4th. The shares were acquired at an average price of $41.29 per share, with a total value of $3,303,200.00. Following the completion of the purchase, the insider now owns 3,472,964 shares in the company, valued at approximately $143,398,683.56. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Target N. V. Biotech bought 60,000 shares of Esperion Therapeutics stock in a transaction dated Monday, December 17th. The stock was purchased at an average cost of $47.73 per share, for a total transaction of $2,863,800.00. Following the purchase, the insider now owns 3,342,964 shares of the company’s stock, valued at approximately $159,559,671.72. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 190,000 shares of company stock worth $8,162,500. 14.50% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the company. BB Biotech AG raised its stake in shares of Esperion Therapeutics by 3.1% in the third quarter. BB Biotech AG now owns 3,282,964 shares of the biopharmaceutical company’s stock valued at $145,665,000 after acquiring an additional 100,000 shares during the period. Meditor Group Ltd increased its stake in Esperion Therapeutics by 1.9% in the 4th quarter. Meditor Group Ltd now owns 2,679,835 shares of the biopharmaceutical company’s stock worth $123,272,000 after buying an additional 50,000 shares during the period. BlackRock Inc. increased its stake in Esperion Therapeutics by 4.1% in the 3rd quarter. BlackRock Inc. now owns 1,878,905 shares of the biopharmaceutical company’s stock worth $83,367,000 after buying an additional 73,673 shares during the period. Vanguard Group Inc. grew its holdings in Esperion Therapeutics by 6.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,649,168 shares of the biopharmaceutical company’s stock worth $73,173,000 after acquiring an additional 99,946 shares in the last quarter. Finally, Vanguard Group Inc grew its holdings in Esperion Therapeutics by 6.5% during the 3rd quarter. Vanguard Group Inc now owns 1,649,168 shares of the biopharmaceutical company’s stock worth $73,173,000 after acquiring an additional 99,946 shares in the last quarter.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Read More: How Short Selling Works

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.